

Announcement of the Sales Partnership Agreement of Epadel in South Korea

This material is an English translation of the press release to be issued on December 16, 2024 in Japanese, and the Japanese release is given priority regarding content and interpretation.

December 16, 2024

Mochida Pharmaceutical Co., Ltd.

Mochida Pharmaceutical Co., Ltd. (Head office: Shinjuku-ku, Tokyo, President: Naoyuki Mochida, hereinafter, "Mochida") announces today that Mochida and Kuhnii Pharm. Co., Ltd. (Head office: Seoul, South Korea, CEO: Han-Kuk Lee, hereinafter, "Kuhnii") entered into a sales partnership agreement for Epadel, a highly purified eicosapentaenoic acid (EPA) ethyl ester formulation sold by Mochida in Japan.

Under the terms of the licensing agreement, Mochida has granted to Kuhnii the exclusive rights to develop and market Epadel in South Korea. Kuhnii will initiate sales of the product following the acquisition of manufacturing and marketing authorization.

As a leading company in high-purity EPA preparations, Mochida is promoting global expansion of Epadel by leveraging alliances in ASEAN countries, such as Thailand and Vietnam, China, Taiwan, and the United States. Through collaboration with Kuhnii, which has extensive experience and a proven track record in pharmaceutical sales in South Korea, we aim to deliver Epadel to patients in the country and contribute to improving their quality of life.

About Epadel

Epadel (generic name: icosapent) is a highly purified EPA ethyl ester formulation developed by Mochida as the world's first medical drug. The active pharmaceutical ingredient is supplied by Nissui Corporation, which has advanced EPA purification technology and the capacity for mass production. It is indicated for "Hyperlipidemia" and "Ulcer, pain and chilliness associated with arteriosclerosis obliterans" in Japan. Since its launch in 1990, it has been taken by many patients.

About Kuhnii

Kuhnii Pharm. Co., Ltd. was founded in Seoul in 1969, and engages in pharmaceutical research, development, manufacturing, and sales. Focusing on the cardiovascular field, it is a pioneer in Korea's omega-3 fatty acid formulations and has led the Korean market in the fields of hyperlipidemia and cardiovascular disease for many years. Kuhnii also has strong interest in doing business in Japan and established OHSONG PHARM, a subsidiary of Kuhnii in 2009, which provides comprehensive services as CDMO & CMO from development & manufacturing to marketing.